FDA approves Admelog, the first short-acting `follow-on` insulin product to treat diabetes
(World News Science)

The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a `follow-on` product (submitted through the agency`s 505(b)(2) pathway). According to the Centers for Disease Control and Prevention, more than 30 million people in the U.S. have diabetes, a chronic disease that affects how the body turns food into energy and the body`s production of natural insulin. Over time, diabetes increases the risk of serious...